<DOC>
	<DOCNO>NCT01550289</DOCNO>
	<brief_summary>The aim study evaluate immunogenicity safety CYD dengue vaccine India adult subject . Primary Objectives : - To describe neutralize antibody response dengue virus serotype first vaccination vaccination CYD dengue vaccine subject . - To describe safety CYD dengue vaccine dose subject . Secondary Objective : - To detect symptomatic dengue case occur time trial .</brief_summary>
	<brief_title>Study Tetravalent Dengue Vaccine Healthy Adult Subjects Aged 18 45 Years India</brief_title>
	<detailed_description>Participants receive 3 dos randomize treatment ( vaccine placebo ) . Flavivirus status determine baseline ( first dose ) vaccine immunogenicity assessment 28 day vaccination . Reactogenicity data collect subject dose . Serious adverse event adverse event special interest collect throughout study .</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Severe Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 18 45 year day inclusion Informed consent form sign date subject ( independent witness , applicable ) Subject able attend schedule visit comply trial procedure Subject good health , base medical history physical examination Subject pregnant , lactating , childbearing potential ( consider nonchildbearing potential , female must postmenopausal least 1 year , surgically sterile , use effective method contraception abstinence least 4 week prior first vaccination least 4 week last vaccination ) Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination Planned participation another clinical trial present trial period Planned receipt vaccine 4 week follow trial vaccination Receipt blood bloodderived product past 3 month , might interfere assessment immune response Known suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) Known seropositivity human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C report subject Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine ( ) use trial vaccine contain substance Chronic illness , opinion investigator , stage might interfere trial conduct completion Current alcohol abuse drug addiction might interfere ability comply trial procedure Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Identified Investigator employee Investigator study center , direct involvement propose study , identify immediate family member ( i.e. , parent , spouse , natural adopt child ) Investigator employee direct involvement propose study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Dengue Fever</keyword>
	<keyword>Dengue Hemorrhagic Fever</keyword>
	<keyword>CYD Dengue Vaccine</keyword>
	<keyword>Dengue Virus</keyword>
	<keyword>Flavivirus</keyword>
</DOC>